Pressmeddelande —
Håkan Gartell appointed acting CEO of A+ Science
Agneta Franksson, former CEO of CRO company A+ Science, has decided to resign. Håkan Gartell has been appointed acting CEO.
Håkan has a bachelor's degree in economics and human geography and has previously been CEO of Vita Nova Ventures AB (publ), Kapitalkraft in Sweden AB, Stock Invest, Civic Fondkommission, Banco Fonder, Aktiespararnas Service AB and stock market editor at Dagens Industri.
Board of director assignments include chairman of Stock Invest, ESMA Fraser, Kindwalls Bil AB (publ) and Phir AB. Board member of Havsfrun Investment AB (publ) and Taurus Energy AB (publ).
The recruitment of a new CEO will begin immediately.
For more information:
Akbar Seddigh, chairman of the board A+ Science Holding, +46 31 703 18 50
Håkan Gartell acting CEO A+ Science, +46 705 14 13 66
Ämnen
- Hälsa, sjukvård, läkemedel
Contract Research Organization A+ Science provides clinical services throughout the life cycle of pharmaceuticals and medical devices. We create customer value through predictability and speed, an approach partly reinforced with what we like to call controlled patient recruitment.
Being part of a strategic CRO partnership, represented in 17 university cities in the Nordic countries and the Baltic States further enhances our offer, creating unmatched access to clinical trial resources in Northern Europe. In addition our Site Management Services provide resources to investigators, making clinical trials even more customizable.
